Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.

In the present study, we evaluated the efficacy and safety of rituximab in combination with standard doxorubicin, bleomycin, vinblastine, and dacarbazine (RABVD) in patients with classical Hodgkin lymphoma (cHL). In this phase 2 study, patients with chemotherapy-naive, advanced-stage cHL were treated with rituximab 375 mg/m(2) weekly for 6 weeks and standard ABVD for 6 cycles. The primary outco...

Hematopathology / NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA

In our experience, certain commonly cited immunophenotypic features of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) are not encountered in day-to-day practice. We reviewed 60 cases of NLPHL (18 women, 42 men; median age, 34 years) to discern immunophenotypic features from a large, single-institution cohort. All cases contained lymphocytic and histiocytic (L&H) cells. These cells expr...

CLINICAL TRIALS AND OBSERVATIONS Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

In the present study, we evaluated the efficacy and safety of rituximab in combination with standard doxorubicin, bleomycin, vinblastine, and dacarbazine (RABVD) in patients with classical Hodgkin lymphoma (cHL). In this phase 2 study, patients with chemotherapy-naive, advanced-stage cHL were treated with rituximab 375 mg/m2 weekly for 6 weeks and standard ABVD for 6 cycles. The primary outcome...

Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma.

Nodular Lymphocyte Predominant Hodgkin Lymphoma With Nodules Resembling T-Cell/Histiocyte Rich B-Cell Lymphoma Differential diagnosis between nodular lymphocyte predominant Hodgkin lymphoma and T-cell/ histiocyte rich B-cell lymphoma Short title: nodular lymphocyte predominant Hodgkin lymphoma

Ludmila Boudová, M. D., Emina Torlakovic, M. D., Jan Delabie, M.D., Peter Reimer, M.D., Beate Pfistner, Ph. D., Sabine Wiedenmann, M. D., Volker Diehl, M.D., Hans-Konrad Müller-Hermelink, M. D., Thomas Rüdiger, M. D. Department of Pathology, Charles University, Pilsen, Czech Republic, Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway, 3 Medizinische Poliklinik, University of ...